TREATMENT OF STAGE I DIFFUSE AGGRESSIVE LYMPHOMAS

I期弥漫性开腹患者的放射治疗 侵袭性淋巴瘤的治疗还算成功。这项研究旨在 提高放射治疗的疗效，消除 用于分期剖腹手术。在本研究中，临床I期和IE患者 接受四个周期的ProMACE-MOPP化疗(在 约75%的原始使用的骨髓抑制药物剂量 ProMACE和MOPP)，随后受累野照射至40Gy.那里 是否有62名可评估的患者进入研究，其中60名(97%)达到 完全缓解。已经有三次复发。7名患者死亡： 两个从未得到完全回应的人，以及一个曾经 在四年多的完全反应中，在她的第二次冠状动脉病变中死亡 动脉搭桥手术。三名患者死于第二种恶性肿瘤。 1例复发患者死于ABMT后的进展性疾病。这个 治疗耐受性良好，没有严重的长期 毒副作用，中位随访时间为7年。这将是困难的 以改善这些结果或减少毒性。

Radiation therapy in laparotomy-staged patients with Stage I diffuse aggressive lymphomas is moderately successful. This study was designed to improve upon the efficacy of radiation therapy and to eliminate the need for staging laparotomy. In this study, clinical Stage I and IE patients are treated with four cycles of ProMACE-MOPP chemotherapy (at approximately 75% of the dosages of myelosuppressive drugs originally used in ProMACE and MOPP) followed by involved field radiation to 40 Gy. There are 62 evaluable patients entered on study of whom 60 (97%) achieved a complete remission. There have been three relapses. Seven patients died: the two who never achieved a complete response, and one woman who had been in complete response for over four years died during her second coronary artery bypass surgery. Three patients have died of a second malignancy. One relapsed patient died of progressive disease following ABMT. The treatment is well tolerated and there have been no serious long-term toxicities with a median follow-up of seven years. It would be difficult to improve upon these results or to decrease the toxicities.